MORE►
Colt Ventures
Left to right: Dr. Shehnaaz Suliman, CEO and board member of ReCode; and David Lockhart, president and chief science officer. [Photos: Jennifer Leahy]
Dallas-Founded Biopharma Firm Raises $120M to Expand its Pipeline
by Kevin Cummings | Jun 29, 2022
ReCode Therapeutics, a biopharmaceutical startup using a non-viral lipid nanoparticle delivery platform for gene therapies, has closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases.
With a research team working out of BioLabs' life sciences facility at Pegasus Park, ReCode aims to grow its global team from about 70 to 100 over the next year.
by Lance Murray |
Mar 27, 2020
The investment from multiple sources, including local early-stage investor Hunt Technology Ventures, is the largest funding round by a startup this year in Dallas-Fort Worth.
MORE►
